-
6m 35sPart 2 | Session 13 Drug coated Balloons vs Drug Eluting Stents: Dr Upul Wickramarachchi
-
26m 20s
-
5m 55sPart 2 | Session 1 Late Stroke after TAVI: Dr Henrik Bjursten
-
8m 5s
-
10m 17sPart 2 | Session 3 The EBC Main Study: Dr David Hildick-Smith
-
7m 3sPart 2 | Session 4 2V-TAVR: Dr Uri Landes
-
4m 29sPart 2 | Session 5 The TriClip bRIGHT Study: Prof Philipp Lurz
-
4m 10sPart 2 | Session 6 The EFFECTIVENES Trial: Prof Philipp Lurz
-
4m 26s
-
7m 30sPart 2 | Session 8 TAVR for BAV Stenosis in Low Surgical Risk Patients: Dr Raj Makkar
-
9m 49sPart 2 | Session 9 2-year Results from the MAGSTEMI Trial: Dr Luis Ortega-Paz
-
3m 33sPart 2 | Session 10 Results from the Early Neo2 Registry: Dr Andreas Rück
-
8m 8sPart 2 | Session 11 Findings From the POEM Study: Dr Giulio Stefanini
In part 1 of this video series, Prof Nicolas Van Mieghem and Dr Joost Daemen host our review series View from the Thoraxcenter. This provides a concise analysis of the highlights of EuroPCR 2021’s Late-Breaking Trials.
The Expert Interviews featured in part 2 provide a short, accessible overview of some selected trials presented at EuroPCR 2021. These videos focus on each study’s design, results and impact on future practice. Some highlights of these interviews include an overview of the Portico™ NG study from Prof Lars Søndergaard and an insightful discussion of TAVR for Bicuspid Aortic Valve Stenosis in a low-risk patient population by Dr Raj Makkar.
More from this programme
Faculty Biographies
Lars Søndergaard
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).